2026-02-06
Imagine a groundbreaking pharmaceutical compound with tremendous therapeutic potential, rendered ineffective by its inability to dissolve in bodily fluids. This scenario represents a common hurdle in drug development, where promising molecules fail due to poor solubility and bioavailability. β-Cyclodextrin (β-CD) has emerged as an elegant scientific solution to this persistent challenge.
This cyclic oligosaccharide, composed of seven glucose subunits linked by α-1,4-glycosidic bonds, possesses a unique molecular architecture that enables remarkable host-guest complexation capabilities. Its structure resembles a molecular cage—featuring a hydrophobic internal cavity surrounded by a hydrophilic exterior—that can encapsulate various hydrophobic compounds, dramatically improving their aqueous solubility, dissolution rates, and biological availability.
The scientific and commercial value of β-CD stems from several distinctive characteristics:
Molecular Weight: 1134.99 g/mol
Molecular Formula: C₄₂H₇₀O₃₅
Solubility: Soluble to 100 mM in DMSO; 10 mM in water
Purity: ≥98%
Storage: Room temperature stable
CAS Registry: 7585-39-9
From a data analysis standpoint, β-CD presents compelling opportunities for pharmaceutical optimization. Quantitative analysis of drug-β-CD interactions enables precise formulation development, allowing researchers to maximize complex stability and controlled release profiles. Advanced data modeling techniques can further predict optimal applications across different industries, supporting evidence-based product development.
As research continues to uncover new applications for this versatile compound, β-cyclodextrin stands poised to address some of the most persistent formulation challenges in pharmaceutical science and related fields.
Senden Sie Ihre Anfrage direkt an uns